What's groundbreaking about the study is that data gathered can be used to create group A streptococcus vaccine
that can save millions of lives.
Maione, "Group B Streptococcus vaccine
: state of the art," Therapeutic Advances in Vaccines, vol.
Edwards disclosed that she is a consultant for and has received research funds from Novartis related to the development of a group B streptococcus vaccine
Safety and immunogenicity of 26-valent group A streptococcus vaccine
in healthy adult volunteers.
*- Group B Streptococcus vaccine
program licensed to Novartis - Intellectual property cross license agreement will allow Novartis to focus on vaccines and Intercell on therapeutic antibodies in this indication*